Ozlem Kandemir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ozlem Kandemir has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Ali Kaya
From the *Department of Clinical Microbiology and Infectious Diseases; †Department of Orthopaedics, Mersin University School of Medicine, Mersin, Turkey; ‡Department of Anatomy, Hacettepe University, School of Medicine, Ankara, Turkey
3 shared publicationsAbtullah Milcan
2 shared publicationsGürbüz Polat
2 shared publicationsA. Akdag
1 shared publicationA. Kaya
Departments of Clinical Microbiology and Infectious Disease, and
1 shared publicationA. Polat
Pathology, University of Mersin School of Medicine, Mersin, Turkey
1 shared publication
Latest Publications
- 24 December 2008
- Vol. 55, 1729-33
Effects of GSTT1, GSTM1 and GSTP1 gene polymorphism on the course of hepatitis B virus infection.
To investigate the effects of GSTT1, GSTM1 and GSTP1 gene polymorphism on the stage of hepatitis B infection. This study included 116 healthy controls, 56 normal carriers of hepatitis B virus, 69 chronic hepatitis B patients and 20 cirrhosis patients. The polymorphism of GSTT1, GSTM1 and GSTP1 were determined with real time PCR with LightCycler instrument using hybridization probes in combination with the LightCycler DNA Master Hybridization Probes Kit (Roche Diagnostics). Multivariate binary logistics regression analyses were used for statistical evaluation. GSTP1 IIe/val genotype was significantly more frequent in the patients with chronic hepatitis B infection and in the patients with cirrhosis (p=0.049 OR: 1.909, 95% CI 0.993-3.668 and p<0.001 OR: 15.238, 95% CI 1.971-117.782 respectively) than in the healthy controls. Similarly, GSTP1 val/val genotype was significantly more frequent in the patients with chronic hepatitis B infection and in the patients with cirrhosis (p=0.006 OR = 6.799, 95% CI 1.712-26.99 and p<0.001, OR: 62.857 95% CI 8.794-449.285 respectively) than in the controls. There was no significant difference in GST IIe/val frequency between the patients with chronic hepatitis B infection and normal carriers of hepatitis B virus, while GST val/val genotype was significantly more frequent in the patients with chronic hepatitis B infection (p=0.030, OR: 6.097, 95% CI 1.192-31.194). Both GST IIe/val and GST val/val genotypes were significantly more frequent in the patients with cirrhosis than in the normal carriers (p=0.001, OR: 12.160 95% CI 1.618-91.360 and p<0.001, OR: 32.154, 95% CI 4.585-225.513 respectively). In addition, there was a significant relation between GSTP1 gene polymorphism and hepatitis stage. In fact, as IIe/val and val/val genotype frequencies significantly increased so did the stage of the disease and tendency towards cirrhosis (p<0.001). The difference in the GSTP1 gene polymorphism did not significantly differ between the healthy controls and the normal carriers of hepatitis B virus. Also, none of the four groups was significantly different concerning the presence of GSTM1 and GSTT1 gene deletions. The results of this study suggested that GSTP1-val (105) gene polymorphism could be associated with the course of chronic hepatitis B infection.
- 24 December 2008
- Vol. 55, 1729-33
Effects of GSTT1, GSTM1 and GSTP1 gene polymorphism on the course of hepatitis B virus infection.
To investigate the effects of GSTT1, GSTM1 and GSTP1 gene polymorphism on the stage of hepatitis B infection. This study included 116 healthy controls, 56 normal carriers of hepatitis B virus, 69 chronic hepatitis B patients and 20 cirrhosis patients. The polymorphism of GSTT1, GSTM1 and GSTP1 were determined with real time PCR with LightCycler instrument using hybridization probes in combination with the LightCycler DNA Master Hybridization Probes Kit (Roche Diagnostics). Multivariate binary logistics regression analyses were used for statistical evaluation. GSTP1 IIe/val genotype was significantly more frequent in the patients with chronic hepatitis B infection and in the patients with cirrhosis (p=0.049 OR: 1.909, 95% CI 0.993-3.668 and p<0.001 OR: 15.238, 95% CI 1.971-117.782 respectively) than in the healthy controls. Similarly, GSTP1 val/val genotype was significantly more frequent in the patients with chronic hepatitis B infection and in the patients with cirrhosis (p=0.006 OR = 6.799, 95% CI 1.712-26.99 and p<0.001, OR: 62.857 95% CI 8.794-449.285 respectively) than in the controls. There was no significant difference in GST IIe/val frequency between the patients with chronic hepatitis B infection and normal carriers of hepatitis B virus, while GST val/val genotype was significantly more frequent in the patients with chronic hepatitis B infection (p=0.030, OR: 6.097, 95% CI 1.192-31.194). Both GST IIe/val and GST val/val genotypes were significantly more frequent in the patients with cirrhosis than in the normal carriers (p=0.001, OR: 12.160 95% CI 1.618-91.360 and p<0.001, OR: 32.154, 95% CI 4.585-225.513 respectively). In addition, there was a significant relation between GSTP1 gene polymorphism and hepatitis stage. In fact, as IIe/val and val/val genotype frequencies significantly increased so did the stage of the disease and tendency towards cirrhosis (p<0.001). The difference in the GSTP1 gene polymorphism did not significantly differ between the healthy controls and the normal carriers of hepatitis B virus. Also, none of the four groups was significantly different concerning the presence of GSTM1 and GSTT1 gene deletions. The results of this study suggested that GSTP1-val (105) gene polymorphism could be associated with the course of chronic hepatitis B infection.
- 1 February 2008
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 20 (1) , 53-57
Comparison of the Efficacy of Tigecycline and Teicoplanin in an Experimental Methicillin-ResistantStaphylococcus aureusOsteomyelitis Model
We evaluated the efficacy of tigecycline and teicoplanin in a rat model of MRSA osteomyelitis. Osteomyelitis was induced with an intramedullary injection of 10(8 )colony-forming units (cfu) of MRSA. After osteomyelitis formation was confirmed on Day 14, infected rats were randomly divided into three groups: tigecycline (n=13), teicoplanin (n=13), and no-treatment control (n=14). A 28-day antibiotic therapy with a subcutaneous injection of tigecycline (14 mg/kg twice daily) or intramuscular administration of teicoplanin (20 mg/kg daily) was administered. Rats were then sacrificed, and the tibias were harvested. The bones were weighed and then cultured. Our results indicated that bacterial growth was significantly reduced in teicoplanin and tigecycline groups, compared to the control group (p=0.019 and p=0.006, respectively). However, no difference was detected between the two antibiotic groups (p=1.000). No bacterial growth was detected in 7 out of 13 and 9 out of 13 specimens of the teicoplanin and tigecycline treated groups, respectively. Although this result was numerically in favor of tigecycline, the difference was not statistically significant (p=0.427). In conclusion, tigecycline, a novel antibiotic, appears as an effective alternative to teicoplanin in the treatment of osteomyelitis caused by MRSA.
- 1 February 2008
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 20 (1) , 53-57
Comparison of the Efficacy of Tigecycline and Teicoplanin in an Experimental Methicillin-ResistantStaphylococcus aureusOsteomyelitis Model
We evaluated the efficacy of tigecycline and teicoplanin in a rat model of MRSA osteomyelitis. Osteomyelitis was induced with an intramedullary injection of 10(8 )colony-forming units (cfu) of MRSA. After osteomyelitis formation was confirmed on Day 14, infected rats were randomly divided into three groups: tigecycline (n=13), teicoplanin (n=13), and no-treatment control (n=14). A 28-day antibiotic therapy with a subcutaneous injection of tigecycline (14 mg/kg twice daily) or intramuscular administration of teicoplanin (20 mg/kg daily) was administered. Rats were then sacrificed, and the tibias were harvested. The bones were weighed and then cultured. Our results indicated that bacterial growth was significantly reduced in teicoplanin and tigecycline groups, compared to the control group (p=0.019 and p=0.006, respectively). However, no difference was detected between the two antibiotic groups (p=1.000). No bacterial growth was detected in 7 out of 13 and 9 out of 13 specimens of the teicoplanin and tigecycline treated groups, respectively. Although this result was numerically in favor of tigecycline, the difference was not statistically significant (p=0.427). In conclusion, tigecycline, a novel antibiotic, appears as an effective alternative to teicoplanin in the treatment of osteomyelitis caused by MRSA.
- 1 May 2007
- Published by Elsevier in Journal of Infection
- Vol. 54 (5) , 439-445
Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms
- 1 May 2007
- Published by Elsevier in Journal of Infection
- Vol. 54 (5) , 439-445
Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms
- 1 January 2005
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 430 (430) , 171-175
Clarithromycin Destroys Biofilms and Enhances Bactericidal Agents in the Treatment of Pseudomonas aeruginosa Osteomyelitis
In this study, the effect of clarithromycin on the destruction of bacterial biofilm in Pseudomonas aeruginosa osteomyelitis was investigated. Foreign body-related osteomyelitis caused by ceftazidime-sensitive Pseudomonas aeruginosa was produced in the tibias of 26 rats. After osteomyelitis was verified on Day 14, 10 rats had ceftazidime (1500 mg/kg/day) given subcutaneously, and 10 rats had ceftazidime given subcutaneously and clarithromycin (100 mg/kg/day, two 50-mg/kg doses every 12 hours) given orally; three rats formed the control group. After a treatment period of 20 days, the tibias and the foreign bodies were removed, cultured, and examined by electron microscopy. The number of microorganisms growing on the bone tissue in the group receiving combined treatment was significantly lower than in the other groups. The number of microorganisms growing on the foreign body in the group receiving only ceftazidime was significantly higher than that of the group receiving combined treatment. Electron microscope examination revealed that the biofilm layer was eradicated in the group that had combined therapy; however, biofilm formation was evident on the foreign body in the group receiving only ceftazidime. Clarithromycin enhanced the activity of concomitantly used bactericidal agents by destroying biofilm on the surface of the materials.
- 1 January 2005
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 430 (430) , 171-175
Clarithromycin Destroys Biofilms and Enhances Bactericidal Agents in the Treatment of Pseudomonas aeruginosa Osteomyelitis
In this study, the effect of clarithromycin on the destruction of bacterial biofilm in Pseudomonas aeruginosa osteomyelitis was investigated. Foreign body-related osteomyelitis caused by ceftazidime-sensitive Pseudomonas aeruginosa was produced in the tibias of 26 rats. After osteomyelitis was verified on Day 14, 10 rats had ceftazidime (1500 mg/kg/day) given subcutaneously, and 10 rats had ceftazidime given subcutaneously and clarithromycin (100 mg/kg/day, two 50-mg/kg doses every 12 hours) given orally; three rats formed the control group. After a treatment period of 20 days, the tibias and the foreign bodies were removed, cultured, and examined by electron microscopy. The number of microorganisms growing on the bone tissue in the group receiving combined treatment was significantly lower than in the other groups. The number of microorganisms growing on the foreign body in the group receiving only ceftazidime was significantly higher than that of the group receiving combined treatment. Electron microscope examination revealed that the biofilm layer was eradicated in the group that had combined therapy; however, biofilm formation was evident on the foreign body in the group receiving only ceftazidime. Clarithromycin enhanced the activity of concomitantly used bactericidal agents by destroying biofilm on the surface of the materials.
- 18 May 2004
- Vol. 51 (57) , 811-4
Fibronectin levels in chronic viral hepatitis and response of this protein to interferon therapy.
In this study, the plasma fibronectin levels in the cases of chronic hepatitis B and C infection and this protein's response to the interferon therapy were examined. Totally, 38 patients with chronic hepatitis, 21 of them being hepatitis B, 17 of them being hepatitis C; and 24 healthy blood donors, as the control group, took part in this study. The quantitative determinations of fibronectin in plasma samples were performed with the Bohring Nephelometer BN 100 (N Antiserum to Human Fibronectin, code no OUND, Dade Behring Marburg GmbH, Marburg Germany). It was observed that the fibronectin plasma levels of the control group were significantly higher than those of the patient group before the therapy (p=0.043). After the interferon therapy of six months, the difference between the fibronectin levels of 16 examined patients before and after the treatment was found to be significant (p=0.001). A negative correlation was detected between the fibronectin levels before the therapy and the inflammatory grade as far as the histopathology of the illness was concerned (r=-0.49), which is a statically significant value (p=0.002). The correlation between the levels of fibronectin and the stage of the fibrosis was found to be insignificant statistically (p=0.225). When comparing the levels before and after the therapy, as far as ALT and AST values were concerned, it was observed that both parameters fell significantly after the therapy (p=0.002). However, no correlation was observed between the fibronectin levels and ALT, AST before and after the therapy. Fibronectin can be a useful marker for showing the hepatic inflammation and damage in the cases of chronic hepatitis, and can also be used in the evaluation of the response to the interferon therapy like other biochemical parameters (ALT, prothrombin activity etc.).
- 18 May 2004
- Vol. 51 (57) , 811-4
Fibronectin levels in chronic viral hepatitis and response of this protein to interferon therapy.
In this study, the plasma fibronectin levels in the cases of chronic hepatitis B and C infection and this protein's response to the interferon therapy were examined. Totally, 38 patients with chronic hepatitis, 21 of them being hepatitis B, 17 of them being hepatitis C; and 24 healthy blood donors, as the control group, took part in this study. The quantitative determinations of fibronectin in plasma samples were performed with the Bohring Nephelometer BN 100 (N Antiserum to Human Fibronectin, code no OUND, Dade Behring Marburg GmbH, Marburg Germany). It was observed that the fibronectin plasma levels of the control group were significantly higher than those of the patient group before the therapy (p=0.043). After the interferon therapy of six months, the difference between the fibronectin levels of 16 examined patients before and after the treatment was found to be significant (p=0.001). A negative correlation was detected between the fibronectin levels before the therapy and the inflammatory grade as far as the histopathology of the illness was concerned (r=-0.49), which is a statically significant value (p=0.002). The correlation between the levels of fibronectin and the stage of the fibrosis was found to be insignificant statistically (p=0.225). When comparing the levels before and after the therapy, as far as ALT and AST values were concerned, it was observed that both parameters fell significantly after the therapy (p=0.002). However, no correlation was observed between the fibronectin levels and ALT, AST before and after the therapy. Fibronectin can be a useful marker for showing the hepatic inflammation and damage in the cases of chronic hepatitis, and can also be used in the evaluation of the response to the interferon therapy like other biochemical parameters (ALT, prothrombin activity etc.).
- Open Access
- 17 November 2003
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 2 (1) , 10
Comparison of the accelerated and classic vaccination schedules against Hepatitis B: three-week Hepatitis B vaccination schedule provides immediate and protective immunity
Hepatitis B virus infection although preventable by vaccination remains an important health issue throughout the world due to its morbidity, mortality and economical losses. Early seroprotection is desirable for people at high risk of exposure. The aim of this study was to determine whether three-week hepatitis B vaccination (on days 0, 10 and 21) provide seroprotection or not. The 120 subjects enrolled into the study were divided into two groups and vaccinated by the classic (months 0, 1, and 2) or the accelerated (days 0, 10, and 21) schedules and antibody response determined on days 30, 60, and 90 and, if below 10 mIU/ml-1, again on day 180. For each individual in the classic group (B) three subjects were enrolled in the accelerated group (A). Recombinant hepatitis B vaccine (Gen-Hevac B, Pasteur) was given as 20 micrograms intramuscular injections via the deltoid muscle. A booster dose on day 365 was administered for each group. Family members of hepatitis B carriers and volunteer health personnel were enrolled into group A. To the B group only volunteers who wanted vaccination against hepatitis B were included. After three doses of vaccine, Anti-HBs titers reached protective levels in both groups. The number of vaccinees with seroprotective levels of Anti-HBs (≥10 mIU/ml-1) on day 30 was 53 (58.9%) in group A and 9 (30.0%) in group B (p < 0.05). On day 60, there was no difference between group A and B, with response rates of 84.4% (n = 76) and 80.0% (n = 24) respectively (p > 0.05). On day 90 there was no difference between group B and group A; with 26 (86.7%) and 79 (87.7%) responders respectively. In both groups those with Anti-HBs levels -1 attained protective levels by day 180. In this study, the three-week vaccination provided protective antibody titers within a shorter time compared to the classic schedule. Therefore, in order to provide rapid antibody production against hepatitis B virus, the accelerated vaccination schedule seems to be a good preference.
- 17 November 2003
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 2 (1) , 10
Open AccessComparison of the accelerated and classic vaccination schedules against Hepatitis B: three-week Hepatitis B vaccination schedule provides immediate and protective immunity
Hepatitis B virus infection although preventable by vaccination remains an important health issue throughout the world due to its morbidity, mortality and economical losses. Early seroprotection is desirable for people at high risk of exposure. The aim of this study was to determine whether three-week hepatitis B vaccination (on days 0, 10 and 21) provide seroprotection or not. The 120 subjects enrolled into the study were divided into two groups and vaccinated by the classic (months 0, 1, and 2) or the accelerated (days 0, 10, and 21) schedules and antibody response determined on days 30, 60, and 90 and, if below 10 mIU/ml-1, again on day 180. For each individual in the classic group (B) three subjects were enrolled in the accelerated group (A). Recombinant hepatitis B vaccine (Gen-Hevac B, Pasteur) was given as 20 micrograms intramuscular injections via the deltoid muscle. A booster dose on day 365 was administered for each group. Family members of hepatitis B carriers and volunteer health personnel were enrolled into group A. To the B group only volunteers who wanted vaccination against hepatitis B were included. After three doses of vaccine, Anti-HBs titers reached protective levels in both groups. The number of vaccinees with seroprotective levels of Anti-HBs (≥10 mIU/ml-1) on day 30 was 53 (58.9%) in group A and 9 (30.0%) in group B (p < 0.05). On day 60, there was no difference between group A and B, with response rates of 84.4% (n = 76) and 80.0% (n = 24) respectively (p > 0.05). On day 90 there was no difference between group B and group A; with 26 (86.7%) and 79 (87.7%) responders respectively. In both groups those with Anti-HBs levels -1 attained protective levels by day 180. In this study, the three-week vaccination provided protective antibody titers within a shorter time compared to the classic schedule. Therefore, in order to provide rapid antibody production against hepatitis B virus, the accelerated vaccination schedule seems to be a good preference.
- 1 July 2003
- Published by Elsevier in Archives of Medical Research
- Vol. 34 (4) , 311-314
Elevation of procalcitonin level in patients with pulmonary tuberculosis and in medical staff with close patient contact
- 1 July 2003
- Published by Elsevier in Archives of Medical Research
- Vol. 34 (4) , 311-314
Elevation of procalcitonin level in patients with pulmonary tuberculosis and in medical staff with close patient contact
- 13 November 2002
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 9 (6) , 419-423
Inducible nitric oxide synthase expression in chronic viral hepatitis and its relation with histological severity of disease
Summary. The role of nitric oxide in the pathogenesis of chronic viral hepatitis is not known. Elevated nitric oxide production is assumed to be responsible for the pathological changes in many inflammatory conditions, mainly via peroxynitrite, a potential oxidant that is produced by the reduction of superoxide anion with nitric oxide. The intensity and the distribution of the immunohistochemical staining of intrahepatic inducible nitric oxide synthase were studied in the biopsy specimens obtained from 63 patients with viral hepatitis and 13 patients with elevated transaminase levels of various aetiologies. Hepatic inducible nitric oxide synthase staining was significantly more intense in the viral hepatitis group (P = 0.000). Inducible nitric oxide synthase staining levels correlated well with the severity of the viral hepatitis using the Knodell's liver histological activity index (r = 0.393, P = 0.002) Among the viral hepatitis group, the pathological distribution of the inducible nitric oxide synthase staining favoured the periportal hepatocytes (zone 1) whereas less staining was observed in parenchymal hepatocytes zone of 2 and 3 and bile duct epithelium. As nitric oxide mediated nitration of hepatocellular proteins is elevated in inflamed hepatic tissues and is correlated with the severity of the disease, we suggest that inducible nitric oxide synthase can possibly have a critical role in the pathogenesis of chronic viral hepatitis.
- 13 November 2002
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 9 (6) , 419-423
Inducible nitric oxide synthase expression in chronic viral hepatitis and its relation with histological severity of disease
Summary. The role of nitric oxide in the pathogenesis of chronic viral hepatitis is not known. Elevated nitric oxide production is assumed to be responsible for the pathological changes in many inflammatory conditions, mainly via peroxynitrite, a potential oxidant that is produced by the reduction of superoxide anion with nitric oxide. The intensity and the distribution of the immunohistochemical staining of intrahepatic inducible nitric oxide synthase were studied in the biopsy specimens obtained from 63 patients with viral hepatitis and 13 patients with elevated transaminase levels of various aetiologies. Hepatic inducible nitric oxide synthase staining was significantly more intense in the viral hepatitis group (P = 0.000). Inducible nitric oxide synthase staining levels correlated well with the severity of the viral hepatitis using the Knodell's liver histological activity index (r = 0.393, P = 0.002) Among the viral hepatitis group, the pathological distribution of the inducible nitric oxide synthase staining favoured the periportal hepatocytes (zone 1) whereas less staining was observed in parenchymal hepatocytes zone of 2 and 3 and bile duct epithelium. As nitric oxide mediated nitration of hepatocellular proteins is elevated in inflamed hepatic tissues and is correlated with the severity of the disease, we suggest that inducible nitric oxide synthase can possibly have a critical role in the pathogenesis of chronic viral hepatitis.